Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
JL Carter, K Hege, J Yang, HA Kalpage, Y Su… - Signal transduction and …, 2020 - nature.com
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and the
second most common form of acute leukemia in children. Despite this, very little …
second most common form of acute leukemia in children. Despite this, very little …
Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies
ARD Delbridge, S Grabow, A Strasser… - Nature Reviews Cancer, 2016 - nature.com
The'hallmarks of cancer'are generally accepted as a set of genetic and epigenetic
alterations that a normal cell must accrue to transform into a fully malignant cancer. It follows …
alterations that a normal cell must accrue to transform into a fully malignant cancer. It follows …
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Leukemia
stem cells (LSCs) drive the initiation and perpetuation of AML, are quantifiably associated …
stem cells (LSCs) drive the initiation and perpetuation of AML, are quantifiably associated …
Cancer drug resistance: an evolving paradigm
C Holohan, S Van Schaeybroeck, DB Longley… - Nature Reviews …, 2013 - nature.com
Resistance to chemotherapy and molecularly targeted therapies is a major problem facing
current cancer research. The mechanisms of resistance to'classical'cytotoxic …
current cancer research. The mechanisms of resistance to'classical'cytotoxic …
Nitrogen-containing heterocycles as anticancer agents: An overview
Background: Cancer is spreading all over the world, and it is becoming the leading cause of
major deaths. Today's most difficult task for every researcher is to invent a new drug that can …
major deaths. Today's most difficult task for every researcher is to invent a new drug that can …
Why do BCL-2 inhibitors work and where should we use them in the clinic?
Intrinsic apoptosis is controlled by the BCL-2 family of proteins but the complexity of intra-
family interactions makes it challenging to predict cell fate via standard molecular biology …
family interactions makes it challenging to predict cell fate via standard molecular biology …
Venetoclax for AML: changing the treatment paradigm
DA Pollyea, M Amaya, P Strati… - Blood advances, 2019 - ashpublications.org
Venetoclax is a specific B-cell lymphoma-2 (BCL-2) inhibitor that can restore activation of
apoptosis in malignancies, the survival of which depends on dysregulation of this pathway …
apoptosis in malignancies, the survival of which depends on dysregulation of this pathway …
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition
N Jacque, AM Ronchetti, C Larrue… - Blood, The Journal …, 2015 - ashpublications.org
Cancer cells require glutamine to adapt to increased biosynthetic activity. The limiting step in
intracellular glutamine catabolism involves its conversion to glutamate by glutaminase (GA) …
intracellular glutamine catabolism involves its conversion to glutamate by glutaminase (GA) …
Targeting mitochondria for cancer therapy
S Fulda, L Galluzzi, G Kroemer - Nature reviews Drug discovery, 2010 - nature.com
Mitochondria are the cells' powerhouse, but also their suicidal weapon store. Dozens of
lethal signal transduction pathways converge on mitochondria to cause the permeabilization …
lethal signal transduction pathways converge on mitochondria to cause the permeabilization …
SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction
H Inuzuka, S Shaik, I Onoyama, D Gao, A Tseng… - Nature, 2011 - nature.com
The effective use of targeted therapy is highly dependent on the identification of responder
patient populations. Loss of FBW7, which encodes a tumour-suppressor protein, is …
patient populations. Loss of FBW7, which encodes a tumour-suppressor protein, is …